Preclinical Imaging Market to worth $4.39 billion by 2030
The Preclinical Imaging Market is projected to grow from USD 3.53 billion in 2025 to USD 4.39 billion by 2030, registering a CAGR of 4.5% during the forecast period.
The report, “Preclinical Imaging Market by Product (Optical Imaging (Bioluminescence), Nuclear Imaging (PET, SPECT), MRI, Reagents (Luciferins, Infrared Dyes), Software), Application (Oncology, Cardiology), End User (Pharmaceutical & Biotechnology Companies, Academic & Research Centers, CROs) – Global Forecast to 2030,” provides a comprehensive analysis of market trends, growth drivers, opportunities, and competitive dynamics across the global preclinical imaging industry.
Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=841
The market is experiencing steady growth due to increasing investments in preclinical research, rising demand for innovative drug discovery, advancements in affordable preclinical imaging technologies, and the growing adoption of non-invasive small-animal imaging techniques. These factors are accelerating the use of advanced imaging systems in pharmaceutical research and biomedical applications.
Among product categories, the optical imaging reagents segment held the largest market share in 2024. The widespread use of optical imaging modalities in preclinical research, coupled with their ability to provide high sensitivity and real-time visualization of biological processes, has significantly contributed to the segment’s leading position. The increasing use of bioluminescence and fluorescence imaging in drug development continues to support market growth.
Based on application, the oncology segment accounted for the largest share of the preclinical imaging market in 2024. The growing global burden of cancer and the need for precise visualization of tumor biology have increased the adoption of molecular imaging technologies. These solutions enable researchers to identify cancer-specific biomarkers, evaluate treatment efficacy, and accelerate the development of targeted therapies.
By end user, pharmaceutical and biotechnology companies represented the largest market segment in 2024. Rising research and development investments, expanding drug pipelines, and the increasing need to improve the efficiency of preclinical studies are driving demand for advanced imaging technologies within these organizations. Biotechnology companies, in particular, continue to leverage preclinical imaging across a broad range of therapeutic research applications.
Geographically, North America dominated the global preclinical imaging market in 2024. The region’s leadership is supported by its well-established research infrastructure, significant funding for life science research, strong presence of pharmaceutical and biotechnology companies, and rapid adoption of advanced imaging technologies for preclinical applications.
Request Sample Pages-https://www.marketsandmarkets.com/requestsampleNew.asp?id=841
Major companies operating in the global preclinical imaging market include **MR Solutions (UK), Mediso Ltd. (Hungary), Sofie (US), FUJIFILM VisualSonics (Canada), MILabs B.V. (Netherlands), Aspect Imaging (Israel), LI-COR Biosciences (US), ICONEUS (France), Advanced Molecular Vision (UK), Vieworks (South Korea), KUB Technologies (US), Mediso Medical Imaging Systems, Medikor (Hungary), TriFoil Imaging (US), IVIM Technology Corp. (South Korea), Cubresa Inc. (Canada), Berthold Technologies GmbH & Co. KG (Germany), Miltenyi Biotec (Germany), AI4R (France), Bruker Corporation (US), and Revvity, Inc. (US). These companies are focused on product innovation, strategic collaborations, and expanding their global presence to strengthen their market position.
Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103, Delray Beach, FL 33445
City: Florida
State: Florida
Country: United States
Website: https://www.marketsandmarkets.com
